They did not assess Bcl-2 or Bcl-xL expression levels; however, their data are compelling and further support the use of Obatoclax to abrogate pro-survival Bcl-2 family member-mediated intrinsic chemoresistance in bladder cancers. The gene discussed is BCL2L1; the disease is urinary bladder cancer.